11 results about "Virus strain" patented technology

This invention discloses a targeted adjuvant influenza vaccine composition for atrial fibrillation patients with atrial fibrosis. The vaccine antigen components are selected from the surface antigens of currently prevalent influenza virus strains, such as hemagglutinin (HA) and neuraminidase (NA). High-purity influenza virus antigens are prepared through cell culture or recombinant DNA technology. For example, influenza virus is cultured using Madin-Darby canine kidney (MDCK) cells, and purified through centrifugation, filtration, and chromatography to obtain high-purity HA and NA antigens. After injection into the human body, the influenza virus antigens (HA and NA) are taken up and processed by antigen-presenting cells (such as macrophages and dendritic cells). The antigen-presenting cells present antigen peptides to T lymphocytes and B lymphocytes, activating a specific immune response. B lymphocytes differentiate into plasma cells with the help of T lymphocytes, producing specific antibodies that recognize and bind to the influenza virus, preventing it from infecting host cells and thus preventing influenza virus infection.

The present invention relates to oncolytic vaccinia viruses and recombinant viruses and methods of use thereof. In particular, the present invention provides a cloned vaccinia virus strain exhibiting enhanced anti-tumor properties and / or reduced immunogenicity, as well as a recombinant vaccinia virus derived therefrom. The present invention also provides recombinant oncolytic virus strains comprising an inactivated mutation in one or more viral genes, and / or one or more heterologous nucleic acids each encoding one or more heterologous gene products. The viruses (e.g., vaccinia viruses, including recombinant vaccinia viruses) provided herein are useful as oncolytic viral therapies (e.g., oncolytic vaccinia viral therapies) for the treatment of cancer. The invention also provides pharmaceutical compositions of the virus, such as vaccinia virus, and methods and uses of the virus, such as vaccinia virus, for the treatment of cancer, as well as nucleic acids encoding the virus.

This invention relates to oncolytic vaccinia viruses, recombinant viruses thereof, and methods of use. Specifically, the invention provides vaccinia virus clone lines and recombinant vaccinia viruses derived therefrom, said vaccinia virus clone lines exhibiting enhanced antitumor properties and / or reduced immunogenicity. The invention also provides recombinant oncolytic virus lines comprising inactivating mutations in one or more viral genes, and / or one or more heterologous nucleic acids each encoding one or more heterologous gene products. The viruses provided by this invention (such as vaccinia viruses, including recombinant vaccinia viruses) can be used as oncolytic virus therapies (such as oncolytic vaccinia virus therapy) for the treatment of cancer. The invention also provides pharmaceutical compositions of viruses (such as vaccinia viruses), methods and uses of viruses (such as vaccinia viruses) for the treatment of cancer, and nucleic acids encoding said viruses.

Provided herein are clonal strains of a vaccinia virus that exhibits enhanced anti-tumor properties and / or reduced immunogenicity, and recombinant vaccinia virus derived from the same. Also provided herein are recombinant oncolytic virus strains that include an inactivating mutation in one or more viral genes, and / or one of more heterologous nucleic acids each encoding one or more heterologous gene products. The viruses, e.g., vaccinia viruses, provided herein, including recombinant vaccinia viruses, can be used as an oncolytic virus therapy, e.g., an oncolytic vaccinia virus therapy, for treating cancer. Also provided herein are pharmaceutical compositions and methods and uses of the viruses, e.g., vaccinia viruses, for treating cancer, as well as nucleic acids encoding the viruses.

To provide newly adapted and / or more potent viruses and / or virus vectors useful for treatment of human diseases.SOLUTION: Disclosed herein is a novel immune-modulating vaccinia virus strain (IOVA) and derivatives thereof with high replication efficiency for use in the medicine. The novel vaccinia virus strain IOVA and derivatives thereof, vectors and recombinants have an ability to replicate in a mammal cancer line and being lytic or, in the case of cancer cells, oncolytic, and elicit an increased capacity to destroy cell-cycle activated cells and / or tumor cells, compared with the gold standard Vaccinia virus WR.SELECTED DRAWING: None

The application provides a launching device of virus strain projectiles and a production device of virus strain chicken embryos. The launching device comprises a blanking mechanism, a launching mechanism and a bearing mechanism. The blanking mechanism is used for conveying the virus strain projectiles to the launching mechanism one by one. The bearing mechanism is used for bearing target chicken embryos to be injected with the virus strain projectiles, and the bearing mechanism can drive the target chicken embryos to move towards the launching mechanism so that the target chicken embryos abut against the launching mechanism. The launching mechanism is located between the bearing mechanism and the blanking mechanism. The launching mechanism is used for accelerating the virus strain projectiles and injecting the virus strain projectiles with a preset speed into eggshells of the target chicken embryos. The launching device of the virus strain projectiles provided in the application can reduce the probability of cracks in the eggshells of the target chicken embryos and improve the success rate of cultivation.

This invention provides a method for creating papaya strains highly resistant to Hainan papaya ringspot virus and Hainan malformation mosaic virus. The method utilizes Hainan PRSV and Hainan PLDMV virus strains. CP Fragments with high expression levels of small RNAs in genes were used to construct Hainan PRSV and Hainan PLDMV viral strains. CP An RNAi fragment of the gene segment is extracted, and an RNAi recombinant vector is constructed. This RNAi recombinant vector is then transformed into papaya to obtain papaya highly resistant to Hainan papaya ringspot virus and Hainan papaya mosaic virus. This invention's highly resistant papaya to Hainan papaya ringspot virus and Hainan papaya mosaic virus has significant application value in improving papaya resistance to Hainan PRSV and Hainan PLDMV.

The present invention relates to an NP antigen peptide of the SFTS virus, the NP antigen peptide including a novel mutation. NP protein sequences of 56 strains collected from the entire genotype were analyzed, consensus sequences of NP proteins were derived therefrom, and then an NP peptide antigen incorporating an amino acid substitution mutation and having improved structural stability was designed through structural analysis modeling. As a result of evaluating immunogenicity and protective ability using an SFTS virus vaccine composition prepared using the NP peptide antigen, it was found that a vaccine composition comprising the NP antigen of the present invention has an excellent ability to produce an immune response and an excellent ability to protect against SFTS virus infection, and thus the NP antigen peptide according to the present invention can be used in a vaccine composition for severe fever with thrombocytopenia syndrome.

Provided is a vaccine against viral infections belonging to the genus Orthopox, the vaccine comprising a non-replicating attenuated vaccinia virus DIs strain.

This invention provides a systemic feline calicivirus (FCV) yolk antibody, its preparation method, and its application. The yolk antibody is prepared using a novel, highly pathogenic FCV strain, CC475, whose cDNA sequence is shown in SEQ ID NO.1. This strain belongs to the VS-FCV strain, which causes fatal systemic disease in cats. It has low homology with classic feline caliciviruses. The yolk antibody prepared using this VS-FCV strain exhibits high titer, good stability, and rapid efficacy, and can be used for rapid treatment or emergency prevention of systemic feline calicivirus infection with a high protection rate.

The application belongs to the technical field of biological medicine, and particularly relates to a nasopharyngeal carcinoma high-risk EB virus strain analysis detection kit and a method and application thereof. The application relates to the technical field of EBV detection. The application reports three unreported nasopharyngeal carcinoma high-risk EB virus SNPs A7001T / A7012G / A7016T, and highly links to the previously reported T6999G highly linked target EBV EBER2. According to the above finding, the application develops a nasopharyngeal carcinoma high-risk EB virus strain rapid typing detection technology, which comprises the following components: a universal primer, a fluorescent probe, NTC, a wild-type quality control product and a mutant quality control product. The technology provided by the application can realize quantitative and typing detection of the nasopharyngeal carcinoma high-risk EB virus strain, and the lower limit of detection is 156 copies / mL of plasma.